Integrating TBS may offer a more comprehensive view of tumor burden, helping identify individuals who may benefit from additional imaging.5 We hypothesized that combining tumor burden with dynamic, time-updated AFP measurements throughout the postoperative period may provide a superior model that continually adapts to each patient’s evolving risk profile. The gene discussed is AFP; the disease is neoplasm.